Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3553149 | 0.98 | GBA1 (0.50) | GBA1HRH4HRH3SLC6A4SLC6A2 | |
| SCHEMBL3158864 | 0.89 | EED (0.51) | GBA1HRH4HRH3 | |
| SCHEMBL3467789 | 0.89 | EED (0.51) | GBA1HRH4HRH3 | |
| SCHEMBL3466554 | 0.89 | EED (0.51) | GBA1HRH4HRH3 | |
| SCHEMBL895063 | 0.89 | GBA1 (0.66) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL15649704 | 0.88 | EED (0.50) | GBA1HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL15649703 | 0.88 | EED (0.50) | GBA1HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL4247331 | 0.87 | GBA1 (0.63) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| Bromide SCHEMBL7246786 | 0.87 | GBA1 (0.63) | GBA1HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17296085 | 0.84 | SLC6A2 (0.41) | GBA1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3212201-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI Pharma (FR) | 2017-09-06 | — | — | EP | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2016066582-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| CN-102695546-B | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2014-09-10 | — | — | CN | disclosed |
| EP-2035371-B1 | SUBSTITUTED PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYT1 AND GLYT2 RECEPTOR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| WO-1997023202-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299071-A1 | Substituted phenyl methanone derivatives | CYP11B1, CYP11B2, MC2R | GBA1 920/4885HRH4 474/4885HRH3 431/4885 |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | GBA1 378/4885HRH4 922/4885HRH3 1474/4885 |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | GBA1 189/4885HRH4 3236/4885HRH3 2630/4885 |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | PTGER1, LOXL1, COL1A1 | GBA1 378/4885HRH4 922/4885HRH3 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.